ReviewPublished 25 September 2026CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapyMasuko Katoh · Masaru KatohFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1927389